Literature DB >> 28573611

Lentiviral Vectors Pseudotyped with Filoviral Glycoproteins.

Patrick L Sinn1,2, Jeremy E Coffin2, Natarajan Ayithan3, Kathleen H Holt2, Wendy Maury4.   

Abstract

Pseudotyping lentivirus-based vectors is a strategy used to study conferred vector tropism and mechanisms of envelope glycoprotein function. Lentiviruses and filoviruses both assemble at the plasma membrane and have homotrimeric structural envelope glycoproteins that mediate both receptor binding and fusion. Such similarities help foster efficient pseudotyping. Importantly, filovirus glycoprotein pseudotyping of lentiviral vectors allows investigators to study virus entry at substantially less restrictive levels of biosafety containment than that required for wild-type filovirus work (biosafety level-2 vs. biosafety level-4, respectively). Standard lentiviral vector production involves transient transfection of viral component expression plasmids into producer cells, supernatant collection, and centrifuge concentration. Because the envelope glycoprotein expression plasmid is provided in trans, wild type or variant filoviral glycoproteins from marburgvirus or ebolavirus species may be used for pseudotyping and compared side-by-side. In this chapter we discuss the manufacture of pseudotyped lentiviral vector with an emphasis on small-scale laboratory grade production.

Entities:  

Keywords:  Ebolavirus; Filovirus; Glycoprotein; Lentivirus; Marburgvirus; Production; Pseudotyping; Purification; Titering; Viral vector

Mesh:

Substances:

Year:  2017        PMID: 28573611      PMCID: PMC5761728          DOI: 10.1007/978-1-4939-7116-9_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  35 in total

Review 1.  No false start for novel pseudotyped vectors.

Authors:  David Avram Sanders
Journal:  Curr Opin Biotechnol       Date:  2002-10       Impact factor: 9.740

2.  Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer.

Authors:  Kaoru Yamada; Douglas M McCarty; Victoria J Madden; Christopher E Walsh
Journal:  Biotechniques       Date:  2003-05       Impact factor: 1.993

3.  Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins.

Authors:  Deborah J Watson; Gary P Kobinger; Marco A Passini; James M Wilson; John H Wolfe
Journal:  Mol Ther       Date:  2002-05       Impact factor: 11.454

4.  T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus.

Authors:  Andrew S Kondratowicz; Nicholas J Lennemann; Patrick L Sinn; Robert A Davey; Catherine L Hunt; Sven Moller-Tank; David K Meyerholz; Paul Rennert; Robert F Mullins; Melinda Brindley; Lindsay M Sandersfeld; Kathrina Quinn; Melodie Weller; Paul B McCray; John Chiorini; Wendy Maury
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

5.  Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy.

Authors:  Laura Tuschong; Sherry L Soenen; R Michael Blaese; Fabio Candotti; Linda Mesler Muul
Journal:  Hum Gene Ther       Date:  2002-09-01       Impact factor: 5.695

6.  Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity.

Authors:  S Funke; I C Schneider; S Glaser; M D Mühlebach; T Moritz; R Cattaneo; K Cichutek; C J Buchholz
Journal:  Gene Ther       Date:  2009-02-12       Impact factor: 5.250

7.  Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates.

Authors:  Virginie Sandrin; Bertrand Boson; Patrick Salmon; Wilfried Gay; Didier Nègre; Roger Le Grand; Didier Trono; François-Loïc Cosset
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

8.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

Authors:  Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-21       Impact factor: 11.205

9.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

10.  Lentiviral vector gene transfer to porcine airways.

Authors:  Patrick L Sinn; Ashley L Cooney; Mayumi Oakland; Douglas E Dylla; Tanner J Wallen; Alejandro A Pezzulo; Eugene H Chang; Paul B McCray
Journal:  Mol Ther Nucleic Acids       Date:  2012-11-27       Impact factor: 10.183

View more
  6 in total

1.  Lentiviral vectors transduce lung stem cells without disrupting plasticity.

Authors:  Ashley L Cooney; Andrew L Thurman; Paul B McCray; Alejandro A Pezzulo; Patrick L Sinn
Journal:  Mol Ther Nucleic Acids       Date:  2021-06-24       Impact factor: 10.183

Review 2.  Gene Therapy for Acute Respiratory Distress Syndrome.

Authors:  Jing Liu; David A Dean
Journal:  Front Physiol       Date:  2022-01-17       Impact factor: 4.566

3.  Development of a blocker of the universal phosphatidylserine- and phosphatidylethanolamine-dependent viral entry pathways.

Authors:  Da-Hoon Song; Gustavo Garcia; Kathy Situ; Bernadette A Chua; Madeline Lauren O Hong; Elyza A Do; Christina M Ramirez; Airi Harui; Vaithilingaraja Arumugaswami; Kouki Morizono
Journal:  Virology       Date:  2021-05-10       Impact factor: 3.513

Review 4.  Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease.

Authors:  Laura I Marquez Loza; Eric C Yuen; Paul B McCray
Journal:  Genes (Basel)       Date:  2019-03-14       Impact factor: 4.096

5.  Increased CFTR expression and function from an optimized lentiviral vector for cystic fibrosis gene therapy.

Authors:  Laura I Marquez Loza; Ashley L Cooney; Qian Dong; Christoph O Randak; Stefano Rivella; Patrick L Sinn; Paul B McCray
Journal:  Mol Ther Methods Clin Dev       Date:  2021-02-27       Impact factor: 5.849

6.  Unique Mode of Antiviral Action of a Marine Alkaloid against Ebola Virus and SARS-CoV-2.

Authors:  Mai Izumida; Osamu Kotani; Hideki Hayashi; Chris Smith; Tsutomu Fukuda; Koushirou Suga; Masatomo Iwao; Fumito Ishibashi; Hironori Sato; Yoshinao Kubo
Journal:  Viruses       Date:  2022-04-15       Impact factor: 5.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.